<DOC>
	<DOCNO>NCT00621855</DOCNO>
	<brief_summary>The purpose trial evaluate safety indicator efficacy 4 dos orally administer dabigatran etexilate , administer twice daily , compare placebo give addition dual antiplatelet treatment patient index event ( MI ) high risk new ischaemic cardiovascular event .</brief_summary>
	<brief_title>RE-DEEM Dose Finding Study Dabigatran Etexilate Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion Patients acute coronary syndrome least one additional risk factor cardiovascular complication . Exclusion criteria 1 . Long term treatment oral anticoagulant 2 . Severe/disabling stroke within last 6 month 3 . Conditions associate increased bleeding risk 4 . Anaemia thrombocytopenia 5 . Severe renal impairment 6 . Liver disease 7 . Positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>